<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="135">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159388</url>
  </required_header>
  <id_info>
    <org_study_id>CL1-95012-001</org_study_id>
    <secondary_id>2019-003456-36</secondary_id>
    <nct_id>NCT05159388</nct_id>
  </id_info>
  <brief_title>A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors</brief_title>
  <official_title>A First in Human Phase 1-2 Open-Label, Multicenter, Dose Escalation and Expansion Study of PRS-344/S095012 in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pieris Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Recherches Internationales Servier (I.R.I.S.)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pieris Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human (FIH), phase 1/2, multi center, open-label, dose escalation and&#xD;
      cohort expansion study designed to determine the safety and tolerability of PRS-344/S095012&#xD;
      in patients with advanced and/or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is an open-label, multi-center safety trial of PRS-344/S095012. The trial consists&#xD;
      of two parts, a dose escalation part (phase 1, first-in-human (FIH) and an expansion part&#xD;
      (phase 2a)). The expansion part of the trial will be initiated once the optimal biological&#xD;
      dose (OBD) has been determined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measurements</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of dose-limiting toxicities (DLTs) over the first 28-days of study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Measurements</measure>
    <time_frame>time on trial, average of 6 months</time_frame>
    <description>Incidence of adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>Through study completion up to 24 months</time_frame>
    <description>Overall Response Rate (ORR)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>PRS-344/S095012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRS-344/S095012</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRS-344/S095012</intervention_name>
    <description>PRS-344/S095012 Monotherapy</description>
    <arm_group_label>PRS-344/S095012</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years on the day the consent is signed.&#xD;
&#xD;
          2. Patients with histologically confirmed diagnosis of unresectable, locally advanced or&#xD;
             metastatic solid tumor for which standard treatment options are not available, no&#xD;
             longer effective, or not tolerated.&#xD;
&#xD;
          3. Patient should have a documented disease progression on prior therapy before entry&#xD;
             into this study.&#xD;
&#xD;
          4. Patients must have at least one measurable target lesion as per RECIST 1.1.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          6. Patient with no available archived material must have one or more tumor lesions&#xD;
             amenable to biopsy.&#xD;
&#xD;
          7. Adequate organ function as assessed by laboratory tests within 72 hours prior to the&#xD;
             start of treatment.&#xD;
&#xD;
          8. A female patient must use a highly effective method of birth control during study&#xD;
             treatment and until 120 days after last dose of study treatment.&#xD;
&#xD;
             Dose Expansion&#xD;
&#xD;
          9. Patients who have had prior checkpoint inhibitor (CPI) treatment in the past 6 months&#xD;
             must have documented confirmed radiographic progression from it prior to study entry.&#xD;
&#xD;
         10. Patients must have received and progressed on only one prior regimen in the metastatic&#xD;
             setting comprising an PD-(L)1 plus chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with previously treated brain metastases may participate provided they are&#xD;
             radiologically stable, clinically asymptomatic and are off immunosuppressive therapies&#xD;
             for at least 4 weeks. Low dose of steroid &lt;10 mg/day prednisone or equivalent) is&#xD;
             allowed.&#xD;
&#xD;
          2. Patients who have received prior:&#xD;
&#xD;
               1. Small molecule inhibitors, and/or other similar investigational agent: ≤ 2 weeks&#xD;
                  or 5 half-lives, whichever is shorter.&#xD;
&#xD;
               2. Chemotherapy, other monoclonal antibodies, antibody-drug conjugates, or other&#xD;
                  similar experimental therapies: ≤3 weeks or 5 half-lives, whichever is shorter.&#xD;
&#xD;
               3. Radioimmunoconjugates or other similar experimental therapies ≤6 weeks or 5&#xD;
                  half-lives, whichever is shorter.&#xD;
&#xD;
          3. Patients who have received 4-1BB agonists in the past.&#xD;
&#xD;
          4. Patients who had a major surgery within 4 weeks prior to first administration of IMP.&#xD;
&#xD;
             Dose Expansion:&#xD;
&#xD;
          5. Patient who received therapy with an irinotecan containing regimen.&#xD;
&#xD;
          6. Patient must not be on warfarin, strong cytochrome P450 (CYP) 3A4 inducers, strong&#xD;
             CYP3A4 inhibitors, or strong UGT1A1 inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Demuth, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pieris Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kayti Aviano</last_name>
    <phone>781-605-8632</phone>
    <email>aviano@pieris.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saundra Kirven</last_name>
    <phone>984-364-0284</phone>
    <email>kirven@pieris.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christiane Jungles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor = Phase 1/2</keyword>
  <keyword>Open-label</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>Metastatic</keyword>
  <keyword>PRS-344</keyword>
  <keyword>S095012</keyword>
  <keyword>PRS-344/S095012</keyword>
  <keyword>Anticalin protein</keyword>
  <keyword>Bi-specific</keyword>
  <keyword>4-1BB</keyword>
  <keyword>CD137</keyword>
  <keyword>PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

